On September 9, 2024, Steven Bellon, Chief Scientific Officer of Foghorn Therapeutics Inc (FHTX, Financial), executed a sale of 20,000 shares of the company. Following this transaction, the insider now directly owns 101,957 shares in the company. The shares were sold at a price of $9.50 per share, as detailed in the SEC Filing.
Foghorn Therapeutics Inc (FHTX, Financial) is a biopharmaceutical company focused on discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. This system regulates gene expression, and mutations or defects in this system can lead to cancer and other serious diseases.
Over the past year, Steven Bellon has sold a total of 20,000 shares and has not made any purchases of the company's stock. The insider transaction history for Foghorn Therapeutics Inc shows no insider buys in the past year, with a total of 2 insider sells during the same period.
Shares of Foghorn Therapeutics Inc were trading at $9.50 on the day of the transaction, giving the company a market cap of approximately $512.897 million. According to the GF Value, the stock is currently modestly undervalued, with a GF Value of $12.24 and a price-to-GF-Value ratio of 0.78.
The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company’s past returns and growth, and future business performance estimates from Morningstar analysts.
This insider sale might be of interest to investors tracking insider behaviors and evaluating the valuation metrics of Foghorn Therapeutics Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
